ASXL1 and cancer: Cancer-derived mutations are enriched in functionally important regions of BAP1—within the catalytic domain of BAP1, disrupting the catalytic triad or structural integrity of the domain; and within the ubiquitin binding site or crossover loop, disrupting the binding interface between BAP1 and ASXL1 [8,23].